CCAR2 as a Target for Prevention of Colorectal Cancer.
CCAR2 作为预防结直肠癌的靶点。
基本信息
- 批准号:10565953
- 负责人:
- 金额:$ 54.83万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-04-01 至 2025-02-28
- 项目状态:未结题
- 来源:
- 关键词:AcetylationAcuteAftercareAlternative SplicingAntibodiesApoptosisApoptosis Regulation GeneAttenuatedBindingBiopsyBromodomainCRISPR/Cas technologyCell CycleCell Cycle ProteinsCell DeathCell SurvivalClinicalColonColon CarcinomaColorectal CancerComplexCyclin D1Dietary FactorsDietary IsothiocyanateDoseDown-RegulationDrug CombinationsEndoscopyEngineeringExcisionFamilial Adenomatous Polyposis SyndromeGenetic TranscriptionHDAC3 geneHistone Deacetylase InhibitorHumanIndividualInduction of ApoptosisIsothiocyanatesLinkModelingNuclearNude MiceNull LymphocytesPatientsPolypsPrevention ProtocolsPreventivePrognosisProtein FamilyProteinsRNA BindingRNA ProcessingRNA SplicingRattusReaderRoleSecondary PreventionSignal PathwaySignal TransductionSiteSulforaphaneTertiary Protein StructureTestingTransfectionTransplantationTumor Suppressionc-myc Genescancer cellcolon cancer patientscolon cancer preventioncolorectal cancer preventioncruciferous vegetabledietaryexperimental studyin vivoinhibitormembermutantnoveloverexpressionpatient derived xenograft modelpolyposisprotein protein interactionsynergismtumor
项目摘要
Cell Cycle and Apoptosis Regulator Protein 2 (CCAR2) is overexpressed in human colorectal cancer and is
associated with poor prognosis, due in part to its role as a coactivator of -catenin-dependent transcription.
The dietary preventive agent sulforaphane (SFN) targets CCAR2 interacting protein histone deacetylase 3
(HDAC3) for inhibition, resulting in acetylation of CCAR2, reduced CCAR2/-catenin nuclear interactions, and
attenuated -catenin-dependent transcription. The novel CCAR2 acetylation sites align with a domain linked to
S1 RNA binding, providing a new mechanistic link to alternative RNA splicing by SFN and other dietary isothio-
cyanates (ITCs). Using novel protein domain arrays, bromodomain-containing proteins were identified that
recognized acetylated forms of CCAR2. These acetyl “readers” also were inhibited by JQ1, which binds to
bromodomain and extraterminal (BET) family proteins, and synergized with SFN to inhibit cell viability in colon
cancer cells. CENTRAL HYPOTHESIS: In the prevention of colon cancer by dietary ITCs and mechanistically-
prioritized drug combinations, HDAC3 inhibition leads to acetylation of CCAR2 and changes in protein-protein
interactions that enhance apoptosis via the inhibition of -catenin-dependent transcription and via altered RNA
splicing. Aim 1a: Test the hypothesis that by inhibiting HDAC3, ITCs alter the acetylation status of CCAR2 in
colon cancer cells, with consequences for -catenin signaling and apoptosis induction. Aim 1b: Perform
mechanistic studies on the acetyl readers of CCAR2, and test inhibitors of readers that synergize with SFN.
Aim 1c: Examine the role of CCAR2 and the DBIRD complex in RNA splicing. Aim 2a: Using the polyposis in
rat colon (Pirc) model, extend to working hypothesis in vivo linking HDAC3 inhibition, CCAR2 acetylation,
reduced -catenin signaling and apoptosis induction. Single acute doses of SFN, 6-SFN and 9-SFN will be
tested alone and in combination with JQ1. The most effective agents from Aim 2a will be assessed for tumor
suppression in the Pirc model via primary (Aim 2b) and secondary prevention protocols (Aim 2c). Using
sequential endoscopy and polyp resection in live rats, define the precise timing of HDAC3 protein loss, CCAR2
acetylation, reduced nuclear CCAR2/-catenin interactions, and the downregulation of -catenin targets. Aim
2d: Extend mechanistic studies from Aim 1c linking CCAR2 acetylation to alternative RNA splicing after ITC
treatment into the Pirc model. Aim 3a: In biopsies from FAP patients, establish the translational relevance of
findings in the Pirc model with respect to CCAR2 overexpression and its interactions with -catenin, HDAC3,
and ZIRD. Aim 3b: In colonoids from Pirc and FAP patients, test the hypothesis that SFN, 6-SFN and 9-SFN
alter the acetylation status of CCAR2 and its protein-protein interactions, with consequences for -catenin
signaling and apoptosis induction. Test individual ITCs and their combinations with JQ1. Aim 3c: In nude mice
transplanted with FAP patient-derived xenografts or CRISPR/Cas9-engineered CCAR2-null human colon
cancer cells transfected with CCAR2 WT and acetylation mutants, examine tumor suppression by ITCs±JQ1.
细胞周期和凋亡调节蛋白2(CCAR 2)在人结直肠癌中过表达,
与不良预后相关,部分原因是其作为β-连环蛋白依赖性转录的共激活因子的作用。
膳食预防剂萝卜硫素(SFN)靶向CCAR 2相互作用蛋白组蛋白脱乙酰酶3
(HDAC 3)用于抑制,导致CCAR 2的乙酰化,减少CCAR 2/β-连环蛋白核相互作用,以及
减弱的β-连环蛋白依赖性转录。新的CCAR 2乙酰化位点与连接到
S1 RNA结合,提供了一个新的机制连接到选择性RNA剪接的SFN和其他饮食异硫代-
氰酸酯(ITC)。使用新的蛋白质结构域阵列,鉴定了含溴结构域蛋白,
CCAR 2的乙酰化形式。这些乙酰基“阅读器”也被JQ 1抑制,JQ 1结合到
溴结构域和末端外(BET)家族蛋白,并与SFN协同抑制结肠中的细胞活力
癌细胞中枢假设:在通过饮食ITC和机制预防结肠癌中-
优先的药物组合,HDAC 3抑制导致CCAR 2的乙酰化和蛋白质-蛋白质
通过抑制β-连环蛋白依赖性转录和通过改变RNA的相互作用,
拼接目的1a:检验通过抑制HDAC 3,ITC改变了CCAR 2的乙酰化状态的假设。
结肠癌细胞,导致β-连环蛋白信号传导和凋亡诱导。目标1b:执行
对CCAR 2的乙酰基阅读器的机制研究,以及与SFN协同的阅读器的测试抑制剂。
目的1c:检测CCAR 2和DBIRD复合物在RNA剪接中的作用。目标2a:使用息肉
大鼠结肠(Pirc)模型,扩展到体内工作假设,其将HDAC 3抑制,CCAR 2乙酰化,
降低β-连环蛋白信号传导和凋亡诱导。单次急性剂量的SFN、6-SFN和9-SFN将被
单独测试和与JQ 1组合测试。将对目标2a中最有效的药物进行肿瘤评估
通过一级预防方案(Aim 2b)和二级预防方案(Aim 2c)在Pirc模型中进行抑制。使用
在活体大鼠中连续的内窥镜检查和息肉切除术,确定了HDAC 3蛋白丢失、CCAR 2
乙酰化,减少核CCAR 2/β-连环蛋白相互作用,以及β-连环蛋白靶点的下调。目的
2d:从Aim 1c扩展ITC后将CCAR 2乙酰化连接到可变RNA剪接的机制研究
治疗进入Pirc模式。目的3a:在FAP患者的活检中,确定
Pirc模型中关于CCAR 2过表达及其与β-连环蛋白,HDAC 3,
和ZIRD。目的3b:在来自Pirc和FAP患者的结肠样物质中,检验SFN、6-SFN和9-SFN与Pirc和FAP患者的结肠样物质之间的相互作用的假设。
改变CCAR 2的乙酰化状态及其蛋白质-蛋白质相互作用,
信号传导和凋亡诱导。测试单个ITC及其与JQ 1的组合。目的3c:裸鼠
移植有FAP患者来源的异种移植物或CRISPR/Cas9工程化的CCAR 2缺失的人结肠
用CCAR 2 WT和乙酰化突变体转染的癌细胞检查ITC ± JQ 1的肿瘤抑制。
项目成果
期刊论文数量(63)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
CCAR1 and CCAR2 as gene chameleons with antagonistic duality: Preclinical, human translational, and mechanistic basis.
- DOI:10.1111/cas.14579
- 发表时间:2020-10
- 期刊:
- 影响因子:5.7
- 作者:Johnson GS;Rajendran P;Dashwood RH
- 通讯作者:Dashwood RH
Long noncoding RNAs and sulforaphane: a target for chemoprevention and suppression of prostate cancer.
- DOI:10.1016/j.jnutbio.2017.01.001
- 发表时间:2017-04
- 期刊:
- 影响因子:0
- 作者:Beaver LM;Kuintzle R;Buchanan A;Wiley MW;Glasser ST;Wong CP;Johnson GS;Chang JH;Löhr CV;Williams DE;Dashwood RH;Hendrix DA;Ho E
- 通讯作者:Ho E
BRD9 Inhibition by Natural Polyphenols Targets DNA Damage/Repair and Apoptosis in Human Colon Cancer Cells.
- DOI:10.3390/nu14204317
- 发表时间:2022-10-15
- 期刊:
- 影响因子:5.9
- 作者:Kapoor, Sabeeta;Damiani, Elisabetta;Wang, Shan;Dharmanand, Ravirajan;Tripathi, Chakrapani;Perez, Jorge Enrique Tovar;Dashwood, Wan Mohaiza;Rajendran, Praveen;Dashwood, Roderick Hugh
- 通讯作者:Dashwood, Roderick Hugh
NADPH oxidase overexpression in human colon cancers and rat colon tumors induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP).
- DOI:10.1002/ijc.25610
- 发表时间:2011-06-01
- 期刊:
- 影响因子:6.4
- 作者:Wang, Rong;Dashwood, Wan-Mohaiza;Nian, Hui;Loehr, Christiane V.;Fischer, Kay A.;Tsuchiya, Naoto;Nakagama, Hitoshi;Ashktorab, Hassan;Dashwood, Roderick H.
- 通讯作者:Dashwood, Roderick H.
Divergent roles of p120-catenin isoforms linked to altered cell viability, proliferation, and invasiveness in carcinogen-induced rat skin tumors.
- DOI:10.1002/mc.22630
- 发表时间:2017-07
- 期刊:
- 影响因子:4.6
- 作者:Wang R;Chen YS;Dashwood WM;Li Q;Löhr CV;Fischer K;Ho E;Williams DE;Dashwood RH
- 通讯作者:Dashwood RH
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Roderick H Dashwood其他文献
Roderick H Dashwood的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Roderick H Dashwood', 18)}}的其他基金
Immunoepigenetic targeting of MHC regulators in FAP
FAP 中 MHC 调节因子的免疫表观遗传学靶向
- 批准号:
10677375 - 财政年份:2023
- 资助金额:
$ 54.83万 - 项目类别:
CCAR2 as a Target for Prevention of Colorectal Cancer.
CCAR2 作为预防结直肠癌的靶点。
- 批准号:
10358583 - 财政年份:2008
- 资助金额:
$ 54.83万 - 项目类别:
Dietary HDAC Inhibitors in Colon Cancer Prevention
膳食 HDAC 抑制剂预防结肠癌
- 批准号:
8009888 - 财政年份:2008
- 资助金额:
$ 54.83万 - 项目类别:
Dietary HDAC Inhibitors in Colon Cancer Prevention
膳食 HDAC 抑制剂预防结肠癌
- 批准号:
8213687 - 财政年份:2008
- 资助金额:
$ 54.83万 - 项目类别:
Dietary HDAC Inhibitors in Colon Cancer Prevention
膳食 HDAC 抑制剂预防结肠癌
- 批准号:
7595928 - 财政年份:2008
- 资助金额:
$ 54.83万 - 项目类别:
Dietary HDAC Inhibitors in Colon Cancer Prevention
膳食 HDAC 抑制剂预防结肠癌
- 批准号:
7456211 - 财政年份:2008
- 资助金额:
$ 54.83万 - 项目类别:
Dietary HDAC Inhibitors in Colon Cancer Prevention
膳食 HDAC 抑制剂预防结肠癌
- 批准号:
7758379 - 财政年份:2008
- 资助金额:
$ 54.83万 - 项目类别:
EFFECT TEA CONSUMP ON PHIP BIOAVIAL AT ULTR-LOW DOSE IN HUMAN VOL
超低剂量的茶摄入量对人体体积中 PHIP 生物病毒的影响
- 批准号:
7602424 - 财政年份:2007
- 资助金额:
$ 54.83万 - 项目类别:
Chemoprevention of Colon Cancer, HDAC Inhibition, and Histone Status
结肠癌的化学预防、HDAC 抑制和组蛋白状态
- 批准号:
8288253 - 财政年份:2003
- 资助金额:
$ 54.83万 - 项目类别:
相似海外基金
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 54.83万 - 项目类别:
Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 54.83万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 54.83万 - 项目类别:
Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 54.83万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 54.83万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 54.83万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 54.83万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 54.83万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 54.83万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
- 批准号:
2244994 - 财政年份:2023
- 资助金额:
$ 54.83万 - 项目类别:
Standard Grant














{{item.name}}会员




